| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We evaluated the antitumor effects of anticancer drug, PARP inhibitor (Olaparib) and irradiation to esophageal cancer cell lines. Furthermore, we verified the combinational effects of anticancer drug, PARP inhibitor and irradiation. These anticancer effects were also evaluated in condition using RNAi for RAD51. Moreover. we could revealed the mechanism in expression and enhancement of anticancer effect by over time evaluation of γH2AX and RAD51 under these treatments for esophageal cancer cell lines. We aim to develop novel chemoradiotherapy using synthetic lethality by DNA repair inhibitors for PARP and RAD51 in esophageal cancer in the future.
|
